Replicor is currently developing its nucleic acid polymer (NAP) technology for the treatment of hepatitis B and hepatitis B / hepatitis D (HBV / HDV) co-infections. Its lead NAP candidate, REP 2139 has demonstrated potent, antiviral activity against HBV and HBV / HDV infections in human patients.